Using lung cancer biospecimens from the Sherlock-Lung study, an international team led by National Institutes of Health (NIH) ...
A global phase 2/3, randomized, open-label trial of BNT327/PM8002 in combination with chemotherapy (chemo) in first-line (1L) non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from ...
Combining glecirasib and sitneprotafib shows encouraging efficacy and safety in patients with KRAS G12C-mutated NSCLC.
The Lung Cancer Research Foundation (LCRF), in collaboration with Boehringer Ingelheim, grants two-year $250,000 awards to ...
Initial safety & efficacy in patients with Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) with Driver Genomic Alterations (GA) outside of Classic EGFR Mutations will be presented ...
One thing that we're seeing is lung cancers being diagnosed earlier and earlier, whereas, historically, 75% of lung cancers ...
Lung cancer is tied to tobacco smoking in the public consciousness, but a significant proportion of cases are driven by factors like indoor and outdoor air pollution or ancestral genetic variants.
Small cell lung cancer, or SCLC, is aggressive, lethal and particularly cruel because chemotherapy initially works so well. But within just a few months, SCLC becomes resistant to drugs and dashes ...
FGTI-2734 and sotorasib are synergistic at inhibiting the viability of sotorasib-resistant (Calu-1 and LU99) and sotorasib-sensitive (H2122 and H358) human KRAS G12C lung cancer cells. A breakthrough ...
Initial safety & efficacy in patients with Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) with Driver Genomic Alterations (GA) outside of Classic EGFR Mutations will be presented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback